The FDA recently revealed a warning letter it sent to Integra LifeSciences‘ (NSDQ:IART) TEI Biosciences over four noted violations it found during an inspection of TEI’s Boston-based facilities. The federal watchdog said that it inspected the company’s facilities where it produces collagen-based medical devices, including its Xenform soft tissue repair matrix, from last October to […]
Integra LifeSciences (NSDQ:IART) said today it closed its acquisition of all outstanding shares of TEI Biosciences and TEI Medical. The purchase allows Integra to broaden its portfolio of reconstructive and regenerative wound care products, the Plainsboro, N.J.-based company said. “We are enthusiastic about the strategic fit of these 2 organizations, and the positive impact TEI has […]
Integra LifeSciences (NSDQ:IART) beat expectations for its 2nd-quarter sales and earnings, but the medical device company still lowered its outlook for the rest of the year. SeaSpine Holdings (NSDQ:SPNE), Integra’s spine business spinout, didn’t fare as well with its Q2 preliminaries, missing expectations with its top-line prediction. Integra posted profits of $5.0 million, or 15¢ per share, on sales of […]
Integra LifeSciences (NSDQ:IART) said today that it closed its $312 million acquisition of TEI Biosciences and sister company TEI Medical, expanding its footprint in reconstructive surgery and regenerative wound care. The deal brings TEI’s PriMatrix dermal repair scaffold and a 125-member sales force under the Integra umbrella, that Plainsboro, N.J.-based company said. TEI is based in Waltham, Mass. […]
Integra LifeSciences (NSDQ:IART) said yesterday that it agreed to acquire TEI Biosciences and sister company TEI Medical for $312 million in cash in a bid to expand its footprint in reconstructive surgery and regenerative wound care. The deal, expected to close during the 3rd quarter, brings TEI’s PriMatrix dermal repair scaffold and a 125-member sales force under the […]
Regenerative medicine company TEI Biosciences said that it has been awarded a supply contract by group purchasing organization Novation for its biologic mesh products.
Waltham, Mass.-based TEI Biosciences won the FDA’s green light to launch a U.S. clinical trial evaluating its breast reconstruction device in women who have undergone a mastectomy.